pteridines has been researched along with Dysmyelopoietic Syndromes in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dill, V | 1 |
| Kauschinger, J | 1 |
| Hauch, RT | 1 |
| Buschhorn, L | 1 |
| Odinius, TO | 1 |
| Müller-Thomas, C | 1 |
| Mishra, R | 1 |
| Kyncl, MC | 1 |
| Schmidt, B | 1 |
| Prodinger, PM | 1 |
| Hempel, D | 1 |
| Bellos, F | 1 |
| Höllein, A | 1 |
| Kern, W | 1 |
| Haferlach, T | 1 |
| Slotta-Huspenina, J | 1 |
| Bassermann, F | 1 |
| Peschel, C | 1 |
| Götze, KS | 1 |
| Waizenegger, IC | 1 |
| Höckendorf, U | 1 |
| Jost, PJ | 1 |
| Jilg, S | 1 |
| Geyh, S | 1 |
| Rodríguez-Paredes, M | 1 |
| Jäger, P | 1 |
| Koch, A | 1 |
| Bormann, F | 1 |
| Gutekunst, J | 1 |
| Zilkens, C | 1 |
| Germing, U | 1 |
| Kobbe, G | 1 |
| Lyko, F | 1 |
| Haas, R | 1 |
| Schroeder, T | 1 |
| Zhou, L | 1 |
| Nguyen, AN | 1 |
| Sohal, D | 1 |
| Ying Ma, J | 1 |
| Pahanish, P | 1 |
| Gundabolu, K | 1 |
| Hayman, J | 1 |
| Chubak, A | 1 |
| Mo, Y | 1 |
| Bhagat, TD | 1 |
| Das, B | 1 |
| Kapoun, AM | 1 |
| Navas, TA | 1 |
| Parmar, S | 1 |
| Kambhampati, S | 1 |
| Pellagatti, A | 1 |
| Braunchweig, I | 1 |
| Zhang, Y | 1 |
| Wickrema, A | 1 |
| Medicherla, S | 1 |
| Boultwood, J | 1 |
| Platanias, LC | 1 |
| Higgins, LS | 1 |
| List, AF | 1 |
| Bitzer, M | 1 |
| Verma, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)[NCT04103645] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-11-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pteridines and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow Cells; Cell Cycle Proteins; Female; Gene Expression Regu | 2020 |
2 other studies available for pteridines and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Fe | 2018 |
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
Topics: Aged; Aged, 80 and over; Animals; Antigens, CD34; Bone Marrow; Female; Hematopoiesis; Humans; Lentiv | 2008 |